EGFR and ovarian carcinoma: Pharmaceutical development strategies have largely shifted to combinations of TKIs with chemotherapeutics, targeted therapies, and/or immune modulators for drug-resistant cancers, especially chemotherapy-resistant ovarian cancer [10] and EGFR TKI-resistant NSCLC [20, 21].